Table 2 Summary of HR of miRNA expression in bladder cancer.

From: MicroRNAs with prognostic significance in bladder cancer: a systematic review and meta-analysis

Study

miR

Case number

OS

CSS

RFS

DFS/PFS

Expression associates with bad prognosis

 

High level

Low level

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

 

Veerla 2009

452

11

23

8.6 (3.6–13.6)

 < 0.025

High

 

452*

11

23

8.2 (3.2–13.2)

 < 0.025

High

Dyrskjøt 2009

133b

3.5 (1.58–7.75)P

0.002

High

 

518c*

3.2 (1.49–6.89)P

0.003

High

 

129

3.0 (1.19–7.56)P

0.02

High

 

29c

0.48 (0.23–1)P

0.05

High

Wang 2012

100

48

78

0.10 (0.04–0.6)

0.008

0.12 (0.04–0.77)P

0.01

Low

Yun 2012

200

0.449 (0.239–0.842)

0.013

Low

Zaravinos 2012

21

38

39

8.40 (1.90–37.04)

0.005

4.88 (1.17–20.41)

0.03

High

 

210

38

39

4.35 (1.13–16.67)

0.033

High

 

387

38

39

0.14 (0.03–0.65)

0.012

0.17 (0.03–0.85)

0.031

Low

Puerta-Gil 2012

222

56

57

1.96 (1.10–3.48)

0.023

1.99 (1.05–3.76)

0.034

2.08 (1.23–3.52)

0.006

3.54 (1.54–8.18)P

0.003

High

 

143

56

57

2.28 (1.21–4.31)

0.011

3.01 (1.06–8.59)P

0.039

High

Kim 2013

214

69

69

0.497 (0.254–0.974)

0.041

Low

Wang 2013

31

56

70

0.084 (0.033–0.833)

0.008

0.114 (0.039–1)P

0.01

Low

Rosenbeg 2013

29c*

18

57

0.2 (0.08–0.52)P

 < 0.001

Low

Ratert 2013

141

20

20

0.28 (0.09–0.82)

0.02

Low

 

205

20

20

0.36 (0.13–0.95)

0.04

Low

Pignot 2013

9

36

36

2.37 (1.36–4.15)

0.003

1.86 (1.08–3.12)

0.025

High

 

182

36

36

1.95 (1.09–3.47)

0.024

1.95 (1.11–3.43)

0.021

High

 

200

36

36

1.86 (1.02–3.39)

0.043

1.93 (1.09–3.39)

0.023

High

Zhang 2014

101

46

26

0.451 (0.237–0.735)

0.028

Low

Zhang 2014

222

48

49

6.17 (2.33–10.39)

 < 0.001

High

Lin 2014

26a

56

70

0.185 (0.088–0.762)

0.01

0.192 (0.0891–0.745)D

0.01

Low

Drayton 2014

27a

70

69

0.98 (0.49–1.96)

0.96

0.44 (0.22–0.88)P

0.02

Low

 

27b

63

76

0.94 (0.47–1.90)

0.87

0.38 (0.18–0.80)P

0.01

Low

Zhang 2015

203

79

29

0.359 (0.209–0.616)

 < 0.001

0.154 (0.082–0.288)P

 < 0.001

Low

Zhang 2015

21

28

25

3.32 (1.16–4.74)

0.018

High

Wu 2015

424

53

71

0.40 (0.24–0.69)

0.001

0.152 (0.066–0.350)D

 < 0.001

Low

Wang 2015

141

54

60

0.314 (0.108–0.946)

0.039

0.492 (0.254–0.954)D

0.036

Low

Wang 2015

214

64

65

0.282 (0.160–0.495)

 < 0.001

0.264 (0.149–0.468)

 < 0.001

Low

Wang 2015

155

52

50

7.7 (1.4–14.7)P

0.009

High

Jiang 2015

152

29

30

2.324 (1.093–4.940)

0.028

High

 

148b-3p

29

30

0.872 (0.419–1.812)

0.713

Low

 

3187–3p

29

30

0.483 (0.227–1.028)

0.059

Low

 

15b-5p

29

30

1.023 (0.494–2.120)

0.951

High

 

27a-3p

29

30

0.721 (0.344–1.510)

0.386

Low

 

30a-5p

29

30

0.677 (0.323–1.419)

0.302

Low

Avgeris 2015

143

3.329 (1.346–8.236)

0.009

5.990 (1.351–26.55)P

0.018

High

 

145

2.426 (0.985–5.976)

0.054

4.164 (1.178–14.80)P

0.027

High

 

224

4.168 (0.557–31.183)

0.164

2.654 (0.944–7.460)P

0.064

High

Andrew 2015

34a

63

166

0.57 (0.34–0.93)

0.029

Low

Martínez-Fernández 2015

200

31

30

0.49 (0.25–0.97)

0.041

Low

Zhang 2016

155

130

32

3.497 (1.722–7.099)

0.001

9.466 (1.210–74.066)P

0.032

High

  1. miR: microRNA; HR: hazard ratio; CI: confidence interval; OS: overall survival; CSS: cancer-specific survival; RFS: recurrence-free survival; PFS: progression-free survival;
  2. DFS: disease-free survival; —: not reported.
  3. DDFS; PPFS.